Chen Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chen Shen has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Yawen Zhao
College of Chemical & Pharmaceutical Engineering Hebei University of Science & Technology Shijiazhuang China
3 shared publicationsJiayao Li
College of Chemical & Pharmaceutical Engineering, Hebei University of Science & Technology, Shijiazhuang, China
2 shared publicationsXiaoxiao Zhang
College of Chemical & Pharmaceutical Engineering Hebei University of Science & Technology Shijiazhuang China
2 shared publicationsYongfa Wang
College of Chemical & Pharmaceutical Engineering, Hebei University of Science & Technology, Shijiazhuang, China
2 shared publications- Bin Li
School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China
1 shared publication Farao Zhang
Ningbo MaterChem Technology Co. Ltd. Ningbo China
1 shared publication
Latest Publications
- 31 October 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (11) , 485
Rational design of L-Pantolactone dehydrogenase to enhance the activity of whole-cell biocatalyst
- 31 October 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (11) , 485
Rational design of L-Pantolactone dehydrogenase to enhance the activity of whole-cell biocatalyst
- 24 September 2026
- Published by Wiley in Water and Environment Journal
Sustainable Biodegradation of Antibiotics: Multidimensional Perspectives on Compost Biostimulation Strategies, Sludge Treatment and Enzymatic Biocatalysis
Antibiotic contamination in water, soil and waste has intensified along with the spread of resistance genes. Three biological treatment approaches such as composting, sludge treatment and enzymatic degradation were compared in this review, focusing on removal mechanisms, operational limits and residual risks from by‐products. Previous assessments often addressed these technologies separately or used removal efficiency as the sole metric. However, high parent‐compound removal does not guarantee reduced risk because metabolites may persist and resistance genes can rebound after land application. Among the three, enzymatic oxidation degrades persistent antibiotics rapidly but is constrained by instability and cost. Immobilization on natural polymers, synthetic matrices or nanomaterials can enhance stability and reusability. A cross‐technology comparison reveals that data on by‐product formation and removal kinetics are scarce and that standardized safety criteria accounting for metabolites are lacking. This review aims to guide selection of treatment strategies that balance degradation with ecological safety.
- 24 September 2026
- Published by Wiley in Water and Environment Journal
Sustainable Biodegradation of Antibiotics: Multidimensional Perspectives on Compost Biostimulation Strategies, Sludge Treatment and Enzymatic Biocatalysis
Antibiotic contamination in water, soil and waste has intensified along with the spread of resistance genes. Three biological treatment approaches such as composting, sludge treatment and enzymatic degradation were compared in this review, focusing on removal mechanisms, operational limits and residual risks from by‐products. Previous assessments often addressed these technologies separately or used removal efficiency as the sole metric. However, high parent‐compound removal does not guarantee reduced risk because metabolites may persist and resistance genes can rebound after land application. Among the three, enzymatic oxidation degrades persistent antibiotics rapidly but is constrained by instability and cost. Immobilization on natural polymers, synthetic matrices or nanomaterials can enhance stability and reusability. A cross‐technology comparison reveals that data on by‐product formation and removal kinetics are scarce and that standardized safety criteria accounting for metabolites are lacking. This review aims to guide selection of treatment strategies that balance degradation with ecological safety.
- 3 March 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70260
Current Advances in Paraptosis Inducer Development and Mechanistic Understanding for Anticancer Applications
Paraptosis is an emerging form of programmed cell death (PCD) that is distinct from conventional cell death modalities such as apoptosis, autophagy, necrosis, and pyroptosis. It is characterized by dilation of the endoplasmic reticulum (ER) and/or mitochondria, accompanied by extensive cytoplasmic vacuolation. This process has garnered significant interest within the realm of cancer treatment in recent years. Therefore, this review provides a comprehensive summary of the potential mechanisms underlying paraptosis and highlights recent progress in the development of paraptosis inducers for cancer therapy. These inducers include natural products, synthetic compounds, and anticancer drugs; moreover, they are frequently employed in combination with other therapeutic strategies. Furthermore, these inducers can trigger paraptosis in cancer cells via multiple pathways, thereby providing a promising alternative therapeutic approach for cancer.
- 3 March 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70260
Current Advances in Paraptosis Inducer Development and Mechanistic Understanding for Anticancer Applications
Paraptosis is an emerging form of programmed cell death (PCD) that is distinct from conventional cell death modalities such as apoptosis, autophagy, necrosis, and pyroptosis. It is characterized by dilation of the endoplasmic reticulum (ER) and/or mitochondria, accompanied by extensive cytoplasmic vacuolation. This process has garnered significant interest within the realm of cancer treatment in recent years. Therefore, this review provides a comprehensive summary of the potential mechanisms underlying paraptosis and highlights recent progress in the development of paraptosis inducers for cancer therapy. These inducers include natural products, synthetic compounds, and anticancer drugs; moreover, they are frequently employed in combination with other therapeutic strategies. Furthermore, these inducers can trigger paraptosis in cancer cells via multiple pathways, thereby providing a promising alternative therapeutic approach for cancer.
- 5 December 2025
- Published by Springer Nature in Chemical Papers
- Vol. 80 (3) , 2083-2096
Synergistic application of photocatalysis and biocatalysis in antibiotic degradation: emerging strategies for sustainable environmental remediation
- 5 December 2025
- Published by Springer Nature in Chemical Papers
- Vol. 80 (3) , 2083-2096
Synergistic application of photocatalysis and biocatalysis in antibiotic degradation: emerging strategies for sustainable environmental remediation
- 25 February 2025
- Published by Elsevier in Plant Physiology and Biochemistry
- Vol. 222, 109695
The key role of cytochrome P450s in the biosynthesis of plant derived natural products
- 25 February 2025
- Published by Elsevier in Plant Physiology and Biochemistry
- Vol. 222, 109695
The key role of cytochrome P450s in the biosynthesis of plant derived natural products
- 5 January 2024
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (9) , 5740-5764
Recent Progress on Peroxidase Modification and Application
Peroxdiase is one of the member of oxireductase super family, which has a broad substrate range and a variety of reaction types, including hydroxylation, epoxidation or halogenation of unactivated C-H bonds, and aromatic group or biophenol compounds. Here, we summarized the recently discovered enzymes with peroxidation activity, and focused on the special structures, sites, and corresponding strategies that can change the peroxidase catalytic activity, stability, and substrate range. The comparison of the structural differences between these natural enzymes and the mimic enzymes of binding nanomaterials and polymer materials is helpful to expand the application of peroxidase in industry. In addition, we also reviewed the catalytic application of peroxidase in the synthesis of important organic molecules and the degradation of pollutants.
- 5 January 2024
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (9) , 5740-5764
Recent Progress on Peroxidase Modification and Application
Peroxdiase is one of the member of oxireductase super family, which has a broad substrate range and a variety of reaction types, including hydroxylation, epoxidation or halogenation of unactivated C-H bonds, and aromatic group or biophenol compounds. Here, we summarized the recently discovered enzymes with peroxidation activity, and focused on the special structures, sites, and corresponding strategies that can change the peroxidase catalytic activity, stability, and substrate range. The comparison of the structural differences between these natural enzymes and the mimic enzymes of binding nanomaterials and polymer materials is helpful to expand the application of peroxidase in industry. In addition, we also reviewed the catalytic application of peroxidase in the synthesis of important organic molecules and the degradation of pollutants.
- 28 September 2023
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 121 (1) , 7-25
Microbial P450 repertoire (P450ome) and its application feasibility in pharmaceutical industry, chemical industry, and environmental protection
Cytochrome P450s (CYPs) are heme‐thiolated enzymes that catalyze the oxidation of C‐H bonds in a regio‐ and stereo‐selective manner. CYPs are widely present in the biological world. With the completion of more biological genome sequencing, the number and types of P450 enzymes have increased rapidly. P450 in microorganisms is easy to clone and express, rich in catalytic types, and strong in substrate adaptability, which has good application potential. Although the number of P450 enzymes found in microorganisms is huge, the function of most of the microorganism P450s has not been studied, and it contains a large number of excellent biocatalysts to be developed. This review is based on the P450 groups in microorganisms. First, it reviews the distribution of P450 groups in different microbial species, and then studies the application of microbial P450 enzymes in the pharmaceutical industry, chemical industry and environmental pollutant treatment in recent years. And focused on the application fields of P450 enzymes of different families to guide the selection of suitable P450s from the huge P450 library. In view of the current shortcomings of microbial P450 in the application process, the final solution is the most likely to assist the application of P450 enzymes in large‐scale, that is, whole cell transformation combined with engineering, fusion P450 combined with immobilization technology.
- 28 September 2023
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 121 (1) , 7-25
Microbial P450 repertoire (P450ome) and its application feasibility in pharmaceutical industry, chemical industry, and environmental protection
Cytochrome P450s (CYPs) are heme‐thiolated enzymes that catalyze the oxidation of C‐H bonds in a regio‐ and stereo‐selective manner. CYPs are widely present in the biological world. With the completion of more biological genome sequencing, the number and types of P450 enzymes have increased rapidly. P450 in microorganisms is easy to clone and express, rich in catalytic types, and strong in substrate adaptability, which has good application potential. Although the number of P450 enzymes found in microorganisms is huge, the function of most of the microorganism P450s has not been studied, and it contains a large number of excellent biocatalysts to be developed. This review is based on the P450 groups in microorganisms. First, it reviews the distribution of P450 groups in different microbial species, and then studies the application of microbial P450 enzymes in the pharmaceutical industry, chemical industry and environmental pollutant treatment in recent years. And focused on the application fields of P450 enzymes of different families to guide the selection of suitable P450s from the huge P450 library. In view of the current shortcomings of microbial P450 in the application process, the final solution is the most likely to assist the application of P450 enzymes in large‐scale, that is, whole cell transformation combined with engineering, fusion P450 combined with immobilization technology.
- Open Access
A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia. In this study, a new method based on competitive affinity and tag detection was developed, which aimed to evaluate potent natural inhibitors preventing the interaction of PCSK9/LDLR directly. Herein, natural compounds with efficacy in the treatment of hypercholesterolemia were chosen to investigate their inhibitory activities on the PCSK9/LDLR interaction. Two of them, polydatin (1) and tetrahydroxydiphenylethylene-2-O-glucoside (2), were identified as potential inhibitors for the PCSK9/LDLR interaction and were proven to prevent PCSK9-mediated LDLR degradation in HepG2 cells. The results suggested that this strategy could be applied for evaluating potential bioactive compounds inhibiting the interaction of PCSK9/LDLR and this strategy could accelerate the discovery of new drug candidates for the treatment of PCSK9-mediated hypercholesterolemia.
Open AccessA New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia. In this study, a new method based on competitive affinity and tag detection was developed, which aimed to evaluate potent natural inhibitors preventing the interaction of PCSK9/LDLR directly. Herein, natural compounds with efficacy in the treatment of hypercholesterolemia were chosen to investigate their inhibitory activities on the PCSK9/LDLR interaction. Two of them, polydatin (1) and tetrahydroxydiphenylethylene-2-O-glucoside (2), were identified as potential inhibitors for the PCSK9/LDLR interaction and were proven to prevent PCSK9-mediated LDLR degradation in HepG2 cells. The results suggested that this strategy could be applied for evaluating potential bioactive compounds inhibiting the interaction of PCSK9/LDLR and this strategy could accelerate the discovery of new drug candidates for the treatment of PCSK9-mediated hypercholesterolemia.
- 18 August 2015
- Published by Springer Nature in Apoptosis
- Vol. 20 (10) , 1307-1320
A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects
Thymosin alpha 1 (Tα1) is commonly used for treating several diseases; however its usage has been limited because of poor penetration of the target tissue, such as tumor cells. In the present study, Tα1-iRGD, a peptide by conjugating Tα1 with the iRGD fragment, was evaluated its performance in MCF-7 and MDA-MB-231 human breast cancer cells. Compared with the wild-type peptide, Tα1-iRGD was more selective in binding tumor cells in the cell attachment assay. Furthermore, the MTT assay confirmed that Tα1-iRGD proved more effective in significantly inhibiting the growth of MCF-7 cells in contrast to the general inhibition displayed by Tα1. Further, conjugation of Tα1 with iRGD preserved the immunomodulatory activity of the drug by increasing the proliferation of mouse spleen lymphocytes. Further, compared with Tα1 treatment, Tα1-iRGD treatment of MCF-7 cells considerably increased the number of cells undergoing apoptosis, resulting in a dose-dependent inhibition of cancer cell growth, which was associated with a much better effect on up-regulation of the expression of BCL2-associated X protein (Bax), caspase 9, etc. More importantly, treatment with Ta1-iRGD was more efficacious than treatment with Ta1 in vivo. This study highlights the importance of iRGD on enhancement of cell penetration and tumor accumulation. In summary, our findings demonstrate that the novel modified Tα1 developed in this study has the potential to be used for treating breast cancer.
- 18 August 2015
- Published by Springer Nature in Apoptosis
- Vol. 20 (10) , 1307-1320
A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects
Thymosin alpha 1 (Tα1) is commonly used for treating several diseases; however its usage has been limited because of poor penetration of the target tissue, such as tumor cells. In the present study, Tα1-iRGD, a peptide by conjugating Tα1 with the iRGD fragment, was evaluated its performance in MCF-7 and MDA-MB-231 human breast cancer cells. Compared with the wild-type peptide, Tα1-iRGD was more selective in binding tumor cells in the cell attachment assay. Furthermore, the MTT assay confirmed that Tα1-iRGD proved more effective in significantly inhibiting the growth of MCF-7 cells in contrast to the general inhibition displayed by Tα1. Further, conjugation of Tα1 with iRGD preserved the immunomodulatory activity of the drug by increasing the proliferation of mouse spleen lymphocytes. Further, compared with Tα1 treatment, Tα1-iRGD treatment of MCF-7 cells considerably increased the number of cells undergoing apoptosis, resulting in a dose-dependent inhibition of cancer cell growth, which was associated with a much better effect on up-regulation of the expression of BCL2-associated X protein (Bax), caspase 9, etc. More importantly, treatment with Ta1-iRGD was more efficacious than treatment with Ta1 in vivo. This study highlights the importance of iRGD on enhancement of cell penetration and tumor accumulation. In summary, our findings demonstrate that the novel modified Tα1 developed in this study has the potential to be used for treating breast cancer.